blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2692359

EP2692359 - CANCER IMMUNOPOTIENTING AGENT CONTAINING RANKL ANTAGONIST [Right-click to bookmark this link]
Former [2014/06]POTENTIATOR OF CANCER IMMUNITY CONTAINING RANKL ANTAGONIST
[2017/03]
StatusPatent revoked
Status updated on  18.01.2023
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  05.05.2017
FormerGrant of patent is intended
Status updated on  10.01.2017
FormerExamination is in progress
Status updated on  31.10.2016
Most recent event   Tooltip20.01.2023Revocation of patentpublished on 22.02.2023  [2023/08]
Applicant(s)For all designated states
Oriental Yeast Co., Ltd.
3-6-10, Azusawa Itabashi-ku
Tokyo 174-8505 / JP
[2014/06]
Inventor(s)01 / AKIYAMA, Taishin
c/o The Institute of Medical Science The University of Tokyo
4-6-1 Shirokanedai
Minato-ku
Tokyo 108-8639 / JP
02 / YANAI, Hiromi
c/o The Institute of Medical Science The University of Tokyo
4-6-1 Shirokanedai
Minato-ku
Tokyo 108-8639 / JP
03 / AKIYAMA, Nobuko
c/o The Institute of Medical Science The University of Tokyo
4-6-1 Shirokanedai
Minato-ku
Tokyo 108-8639 / JP
04 / YASUDA, Hisataka
c/o Bioindustry Division
Oriental Yeast Co. Ltd.
3-6-10 Azusawa
Itabashi-ku
Tokyo 174-8505 / JP
 [2014/06]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2017/23]
Former [2014/06]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Application number, filing date12765137.028.03.2012
[2017/23]
WO2012JP59130
Priority number, dateJP2011007916731.03.2011         Original published format: JP 2011079167
[2014/06]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012133914
Date:04.10.2012
Language:JA
[2012/40]
Type: A1 Application with search report 
No.:EP2692359
Date:05.02.2014
Language:EN
[2014/06]
Type: B1 Patent specification 
No.:EP2692359
Date:07.06.2017
Language:EN
[2017/23]
Search report(s)International search report - published on:JP04.10.2012
(Supplementary) European search report - dispatched on:EP20.11.2014
ClassificationIPC:A61K39/395, A61P35/00, A61P37/04
[2017/03]
CPC:
C07K16/2875 (EP,US); A61K39/39558 (US); A61P35/00 (EP);
A61P37/04 (EP); C07K2317/76 (EP,US)
Former IPC [2014/06]A61K45/00, A61K39/395, A61P35/00, A61P37/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/06]
TitleGerman:KREBSIMMUNITÄTSVERSTÄRKER MIT EINEM RANKL-ANTAGONISTEN[2014/06]
English:CANCER IMMUNOPOTIENTING AGENT CONTAINING RANKL ANTAGONIST[2017/03]
French:POTENTIALISATEUR D'IMMUNITÉ ANTICANCÉREUSE CONTENANT UN ANTAGONISTE DE RANKL[2014/06]
Former [2014/06]POTENTIATOR OF CANCER IMMUNITY CONTAINING RANKL ANTAGONIST
Entry into regional phase16.10.2013Translation filed 
16.10.2013National basic fee paid 
16.10.2013Search fee paid 
16.10.2013Designation fee(s) paid 
16.10.2013Examination fee paid 
Examination procedure16.10.2013Examination requested  [2014/06]
16.06.2015Amendment by applicant (claims and/or description)
16.12.2015Despatch of a communication from the examining division (Time limit: M04)
21.04.2016Reply to a communication from the examining division
29.08.2016Despatch of a communication from the examining division (Time limit: M04)
26.10.2016Reply to a communication from the examining division
11.01.2017Communication of intention to grant the patent
21.04.2017Fee for grant paid
21.04.2017Fee for publishing/printing paid
21.04.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.12.2015
Opposition(s)Opponent(s)01  06.03.2018    ADMISSIBLE
Dehmel & Bettenhausen
Herzogspitalstr. 11
80331 Munich / DE
Opponent's representative
Rückerl, Florian
Dehmel & Bettenhausen
Patentanwälte PartmbB
Herzogspitalstraße 11
80331 München / DE
 [2018/15]
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
22.03.2018Invitation to proprietor to file observations on the notice of opposition
01.08.2018Reply of patent proprietor to notice(s) of opposition
03.06.2019Date of oral proceedings
27.06.2019Despatch of minutes of oral proceedings
27.06.2019Date of despatch of rejection of opposition
19.11.2022Legal effect of revocation of patent [2023/08]
11.01.2023Despatch of communication that the patent will be revoked
Appeal following opposition27.08.2019Appeal received No.  T2428/19
04.11.2019Statement of grounds filed
09.11.2022Result of appeal procedure: revocation of the patent
11.01.2023Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
18.03.2014Renewal fee patent year 03
23.03.2015Renewal fee patent year 04
14.03.2016Renewal fee patent year 05
13.03.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.03.2012
AL07.06.2017
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
[2020/34]
Former [2020/31]HU28.03.2012
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
Former [2020/27]HU28.03.2012
AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
Former [2020/15]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
Former [2020/08]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
Former [2019/12]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
BE31.03.2018
Former [2019/09]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
IE28.03.2018
LU28.03.2018
Former [2019/04]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
LU28.03.2018
Former [2018/52]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/25]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/21]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/11]AT07.06.2017
CZ07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/10]AT07.06.2017
CZ07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2018/09]EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/52]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/50]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/49]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
NO07.09.2017
GR08.09.2017
Documents cited:Search[XI]WO2008088594  (ANAPTYS BIOSCIENCES INC [US], et al) [X] 1,2,4,5 * paragraphs [0006] , [ 0008] , [00629] , [ 00633]; claims 2-5,18-21 * [I] 3;
 [XI]WO2010022120  (REGENERON PHARMA [US], et al) [X] 1,2,4,5 * paragraphs [0027] , [0080]; claims 1,14-17 * [I] 3;
 [X]  - MARIE-LIESSE ASSELIN-LABAT ET AL, "Control of mammary stem cell function by steroid hormone signalling", NATURE, (20100411), vol. 465, no. 7299, doi:10.1038/nature09027, ISSN 0028-0836, pages 798 - 802, XP055152179 [X] 1-5 * page 800, column 2, paragraph 2 - page 801, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1038/nature09027
International search[A]JP2005515159  (IMMUNEX CORP.);
 [A]JP2005515752  (SMITHKLINE BEECHAM CORP.);
 [A]WO2011017294  (SCHERING CORP [US], et al);
 [A]  - YASUSHI KUBOTA ET AL., "Role of Osteoclasts Targeting Agents, Bisphosphonates and RANKL Inhibitor, Against Cancer Stem Cells", SAISHIN IGAKU, (20110310), vol. 66, no. 3, pages 19 - 24, XP008171090
 [A]  - SHUNJI TAKAHASHI, "Hone Ten'i ni Taisuru Kotai Ryoho -RANKL Kotai (denosumab)", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, (2006), vol. 219, no. 1, pages 91 - 96, XP008171092
 [A]  - YOSHIYA TOMIMORI ET AL., "Hakotsu Saibo Bunka Inshi RANKL Oyobi RANKL Chuwa Kotai no in vivo eno Oyo", BIO CLINICA, (20100110), vol. 25, no. 1, pages 70 - 74, XP008171259
 [A]  - TAISHIN AKIYAMA ET AL., "RANKL Signal ni yoru Men'eki Hassei to Men'eki Kan'yo no Seigyo", EXPERIMENTAL MEDICINE, (2009), vol. 27, no. 6, pages 865 - 870, XP008171260
 [A]  - TAISHIN AKIYAMA, "Kyosen Izonteki na Jiko Men'eki Kan'yo Yudo no Bunshi Kiban", MINOPHAGEN MEDICAL REVIEW, (2009), vol. 54, no. 3, pages 155 - 165, XP008171091
by applicantEP0125023
 WO9215679
 WO9411523
 WO9602576
 US5545806
 US5612205
 US5814318
 US5981175
 JP2002509430
 JP3523650B
 US7145056
 JP2011079167
    - KYEWSKI B ET AL., ANNU REV IMMUNOL., (2006), vol. 24, pages 571 - 606
    - GOTTER J ET AL., J EXP MED., (2004), vol. 199, pages 155 - 66
    - STOLINA M ET AL., ADV EXP MED BIOL., (2007), vol. 602, pages 143 - 50
    - GONZALEZ-SUAREZ E ET AL., NATURE, (2010), vol. 468, pages 103 - 7
    - AKIYAMA T ET AL., IMMUNITY, (20080919), vol. 29, no. 3, pages 423 - 37
    - AKIYAMA T ET AL., SCIENCE, (2005), vol. 308, pages 248 - 51
    - DOUGALL WC ET AL., CURR OPIN SUPPORT PALLIAT CARE, (2007), vol. 1, pages 317 - 22
    - VANDAMME, A. M. ET AL., EUR. J. BIOCHEM., (1990), vol. 192, pages 767 - 775
    - EBERT, K.M. ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702
    - TOMIZUKA, K. ET AL., NATURE GENET., (1997), vol. 16, pages 133 - 143
    - ISHIDA I. ET AL., CLONING AND STEM CELLS, (2002), vol. 4, pages 85 - 95
OppositionEP2165716
    - SCHMIEDEL et al., "Abstract 2164: RANKL Expressed by Acute Myeloid Leukemia Cells Impairs NK CellMediated Immune Surveillance.", Blood, (20101119), vol. 116, no. 21, page 893, XP055470938
    - FURUYA et al., "Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor- B Ligand-neutralizing Antibody: EVIDENCE FOR BONE ANABOLIC EFFECT OF PARATHYROID HORMONE IN MICE WITH FEW OSTEOCLASTS", J Biol Chem., (20110823), vol. 286, no. 42, pages 37023 - 37031, XP055355832

DOI:   http://dx.doi.org/10.1074/jbc.M111.246280
    - STOTINA M et al., "RANKL INHIBITION: FROM MICE TO MEN (AND WOMEN)", Adv Exp Med Biol., (20070000), vol. 602, pages 143 - 150, XP055470947
    - ANTONY et al., "Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?", J Immunother., (20020000), vol. 25, no. 3, pages 202 - 206, XP055470952
    - HANADA et al., "RANKL/RANK-beyond bones", J Mol Med, (20110329), vol. 89, no. 7, pages 647 - 656, XP019914237

DOI:   http://dx.doi.org/10.1007/s00109-011-0749-z
    - TAN et al., "Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling", Nature, (20110224), vol. 470, no. 7335, pages 548 - 553, XP055009739

DOI:   http://dx.doi.org/10.1038/nature09707
    - PENGHUI ZHOU, "ENHANCED ANTI-TUMOR IMUNITY BY BREAKING IMMUNE TOLERANCE", Dissertation, (20090000), XP055470964
    - HIKOSAKA et al., "The Cytokine RANKL Produced by Positively Selected Thymocytes Fosters Medullary Thymic Epithelial Cells that Express Autoimmune Regulator", immunity, (20080919), vol. 29, no. 3, pages 438 - 450, XP055470993

DOI:   http://dx.doi.org/10.1016/j.immuni.2008.06.018
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.